Hepatitis/MASH

The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.

Latest News

Hepatitis C virus model, 3D illustration. A virus consists of a protein coat, capsid, surrounding RNA and outer lipoprotein envelope with two types of glycoprotein spikes, E1 and E - Image credit: Dr_Microbe | stock.adobe.com
Glecaprevir/Pibrentasvir Combination Receives FDA Approval Expanded Indication for Acute HCV

June 11th 2025

The expansion marks glecaprevir/pibrentasvir as the first and only indicated direct-acting antiviral approved for acute hepatitis C virus (HCV) infection.

Pharmacist-Led HCV Program Uncovers Syndemic Risks, Supports Expanded Screening
Pharmacist-Led HCV Program Uncovers Syndemic Risks, Supports Expanded Screening

June 10th 2025

Hepatocellular carcinoma -- Image credit: sinhyu | stock.adobe.com
Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

June 6th 2025

Metabolic dysfunction-associated steatohepatitis (MASH) -- Image credit: Angelov | stock.adobe.com
GLP-1 Receptor Agonists and FGF21 Analogues May Be Key Treatments for MASH-Related Cirrhosis

June 4th 2025

Liver with fibrosis -- Image credit: Rasi | stock.adobe.com
Elecsys PRO-C3 Test Aims to Improve Precision Evaluation of Liver Fibrosis Severity

May 30th 2025

<1
...
3637383940